deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT04480554

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 (AMOHI-1)

Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment

Sponsor: Ho Chi Minh City CDC

Conditions Antiretroviral Treatment Buprenorphine HIV-1-infection Immune Activation Inflammation Methadone Naltrexone Opioid-use Disorder
Interventions Buprenorphine/naloxone Methadone XR-Naltrexone
Updated 15 times since 2020 Last updated: Jul 10, 2024 Started: Jan 30, 2023 Primary completion: Jun 30, 2025 Completion: Jun 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Antiretroviral Treatment and Buprenorphine and is currently actively recruiting participants. Ho Chi Minh City CDC leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Oct 2021 · 5 months · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Mar 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 10 earlier versions

  1. Feb 2023 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE2

  2. Dec 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

  3. Sep 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE2

  4. Jun 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  5. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE2

  6. Feb 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

  7. Oct 2021 — Feb 2022 [monthly]

    Not Yet Recruiting PHASE2

  8. May 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

  9. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2

  10. Aug 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ho Chi Minh City CDC
  • Institute of Applied Medicine and Epidemiology (IMEA)
  • National Institute of Drug Abuse
  • The Wistar Institute
  • University of Pennsylvania
Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations